

constituency. Input from the meeting participants will be used to complete a situation analysis (Phase I) in a three-phase process to develop a national outreach/marketing strategy to increase public participation in recreational fishing and boating.

Dated: October 17, 1997.

**Jamie Rappaport Clark,**

*Director.*

[FR Doc. 97-28628 Filed 10-28-97; 8:45 am]

BILLING CODE 4310-55-M

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Importer of Controlled Substances; Notice of Registration**

By Notice dated July 21, 1997, and published in the **Federal Register** on August 26, 1997, (62 FR 45271), Applied Science Labs, Inc., A Division of Altech Associates, Inc., 2701 Carolean Industrial Drive, P.O. Box 440, State College, Pennsylvania 16801, made application by renewal to the Drug Enforcement Administration to be registered as an importer of the basic classes of controlled substances listed below:

Drug	Schedule
Heroin (9200) .....	I
Morphine (9300) .....	II

DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Applied Science Labs to import listed controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. Therefore, pursuant to Section 1008(a) of the Controlled Substances Import and Export Act and in accordance with Title 21, Code of Federal Regulations, Section 1301.34, the above firm is granted registration as an importer of the basic classes of controlled substances listed above.

Dated: October 17, 1997.

**John H. King,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 97-28558 Filed 10-28-97; 8:45 am]

BILLING CODE 4410-09-M

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[DEA #171I]

**Controlled Substances: 1997 Aggregate Production Quota**

**AGENCY:** Drug Enforcement Administration (DEA), Justice.

**ACTION:** Interim notice establishing a 1997 aggregate production quota and request for comments.

**SUMMARY:** This interim notice establishes a revised 1997 aggregate production quota for codeine (for sale), a Schedule II controlled substance, as required under the Controlled Substances Act of 1970.

**DATES:** This is effective on October 29, 1997. Comments must be received on or before November 28, 1997.

**ADDRESSES:** Send comments or objections to the Acting Deputy Administrator, Drug Enforcement Administration, Washington, D.C. 20537, Attn.: DEA Federal Register Representative/CCR.

**FOR FURTHER INFORMATION CONTACT:** Frank L. Sapienza, Chief, Drug and Chemical Evaluation Section, Drug Enforcement Administration, Washington, D.C. 20537, (202) 307-7183.

**SUPPLEMENTARY INFORMATION:** Section 306 of the Controlled Substances Act (21 U.S.C. 826), requires the Attorney General to establish aggregate production quotas for controlled substances in Schedules I and II each year. This responsibility has been delegated to the Administrator of the DEA pursuant to Section 0.100 of Title 28 of the Code of Federal Regulations. The Administrator, in turn, has re delegated this function to the Acting Deputy Administrator of the DEA pursuant to Section 0.014 of Title 28 of the Code of Federal Regulations.

The DEA established revised 1997 aggregate production quotas for controlled substances in Schedules I and II, including codeine (for sale), in a **Federal Register** notice published on August 15, 1997 (62 FR 43750). Since publication of the revised 1997 aggregate production quotas, DEA has received information which necessitates an immediate increase in the revised 1997 aggregate production quota for codeine (for sale). The increase for codeine (for sale) is necessary to meet additional and unforeseen domestic manufacturing needs and export requirements. For these reasons, an interim notice is being published.

Therefore, under the authority vested in the Attorney General by Section 306

of the Controlled Substances Act of 1970 (21 U.S.C. 826), delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations, and re delegated to the Acting Deputy Administrator, pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations, the Acting Deputy Administrator hereby orders that the revised aggregate production quota for the following controlled substance, expressed in grams of anhydrous base, be established as follows:

Basic class	Established revised 1997 quota
Codeine (for sale) .....	58,140,000

All interested persons are invited to submit their comments in writing regarding this interim notice.

The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. This action has been analyzed in accordance with the principles and criteria contained in Executive Order 12612, and it has been determined that this matter does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment.

The Acting Deputy Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601 *et seq.* The establishment of annual aggregate production quotas for Schedule I and II controlled substances is mandated by law and by international treaty obligations. Aggregate production quotas apply to approximately 200 DEA registered bulk and dosage from manufacturers of Schedule I and II controlled substances. The quotas are necessary to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and the establishment and maintenance of reserve stocks. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Acting Deputy Administrator has determined that this action does not require a regulatory flexibility analysis.

Dated: October 22, 1997.

**James S. Milford,**

*Acting Deputy Administrator.*

[FR Doc. 97-28557 Filed 10-28-97; 8:45 am]

BILLING CODE 4410-09-M